Skip to Main Content

Our Endosomal Escape Vehicle (EEV™) Platform

Engaging Disease-Causing Targets Previously Considered Inaccessible and Undruggable

about
75
%

~75% of disease-causing targets are located inside cells.1 Yet, most are still considered inaccessible.

about
1-2
%

Only ~1-2% of conventional biological therapeutics reach their intended target.2

about
50
%

Based on preclinical studies, ~HALF of EEV-therapeutics reach their intended target.3

Screenshot of video about our EEV platform and our mission Play Video

The Challenge with Conventional Intracellular Therapeutics

Delivering a therapy into the cell presents two fundamental challenges:

  1. Getting it inside the cell.
  2. Then, most importantly, avoiding the cell’s natural clearing systems so it can reach the intended target.

Small molecules can permeate cell membranes but then tend to be rapidly cleared by the body before they reach the intended tissue, may fail to bind effectively to their intended target and can be associated with off-target effects.

Biological therapeutics are highly targeted and potent but limited in their ability to reach intracellular targets of interest. These limitations often necessitate high therapeutic doses and can be associated with less-than-optimal therapeutic activity.

Our Proprietary EEV™ Platform Offers a Potential Solution

Diagram showing a therapeutic modality attached to an EEV A highly specific and potent therapeutic modality An EEV from our library of proprietary peptides. The cyclic structure ensures rigidity and stability.

We believe we have discovered the solution to the fundamental challenges of intracellular therapeutics. Our proprietary EEV™ Platform is designed to engage disease-causing targets previously considered inaccessible and undruggable.

Want to learn more about how our EEV-therapeutics evade the cell’s natural clearing systems to reach their disease-causing target? View the animation below: 

Screenshot of video about how our EEV-therapeutics work Play Video

Our EEV™ Platform has the potential to translate into substantial improvements in efficacy, safety and tolerability of future medicines.

Broad Therapeutic Potential

EEVs can facilitate the delivery of various types of therapeutic modalities into a wide range of organs, tissue and cells.

Learn more about our diverse and expanding pipeline

Graphic depicting Oligonucleotides
Graphic depicting Enzymes
Graphic depicting Antibodies
Our EEV™ Platform is versatile and modular, with potential utility across:
  • Neuromuscular diseases
  • Immunological diseases
  • Ocular diseases
  • Metabolic diseases

Visit our Manuscripts and Presentations pages to learn more

References
  1. 1.

    Verdine GL, Walensky LD. The challenge of drugging undruggable targets in cancer: lessons learned from targeting BCL-2 family members. Clin Cancer Res. 2007;13(24):7264-70. doi:10.1158/1078-0432.CCR-07-2184.

  2. 2.

    Kilchrist KV, et al. Gal8 visualization of endosome disruption predicts carrier-mediated biologic drug intracellular bioavailability. ACS Nano. 2019;13(2):1136-52. doi:10.1021/acsnano.8b05482.

  3. 3.

    Data on file. Entrada Therapeutics.